Revises Full Year 2025 Guidance
|
|
Three months ended |
|
Six months ended |
||||
|
|
|
|
|
||||
|
|
2025 |
|
2024 |
|
2025 |
|
2024 |
|
|
|
|
|
|
|
|
|
|
(In millions, except per-share results) |
|||||||
|
Premium Revenue |
|
|
|
|
|
|
|
|
Total Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP: |
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
EPS – Diluted |
|
|
|
|
|
|
|
|
Medical Care Ratio (MCR) |
90.4% |
|
88.6% |
|
89.8% |
|
88.6% |
|
G&A Ratio |
6.2% |
|
7.0% |
|
6.6% |
|
7.1% |
|
After-tax Margin |
2.2% |
|
3.0% |
|
2.4% |
|
3.0% |
|
|
|
|
|
|
|
|
|
|
Adjusted: |
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
EPS – Diluted |
|
|
|
|
|
|
|
|
G&A Ratio |
6.1% |
|
6.9% |
|
6.4% |
|
7.0% |
|
After-tax Margin |
2.6% |
|
3.5% |
|
2.8% |
|
3.4% |
|
|
|
|
|
|
|
|
|
|
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release. |
|||||||
Quarter Highlights
-
As of
June 30, 2025 , the Company served approximately 5.7 million members, an increase of 167,000 members compared toJune 30, 2024 . -
Premium revenue was approximately
$10.9 billion for the second quarter of 2025, an increase of 15% year over year. -
GAAP net income was
$4.75 per diluted share for the second quarter of 2025, a decrease of 8% year over year. -
Adjusted net income was
$5.48 per diluted share for the second quarter of 2025, a decrease of 6% year over year. -
The Company now expects its full year 2025 adjusted earnings to be no less than
$19.00 per diluted share and reaffirms its premium revenue guidance of approximately$42 billion . -
New store embedded earnings remain at
$8.65 per diluted share.
“Our second quarter results and revised full year outlook reflect a challenging medical cost trend environment,” said
Premium Revenue
Premium revenue was approximately
Net Income
GAAP net income for the second quarter of 2025 was
Medical Care Ratio (MCR)
- The consolidated MCR for the second quarter of 2025 was 90.4%.
- The Medicaid MCR for the second quarter of 2025 was 91.3%. The Company experienced medical cost pressure due to continued utilization of behavioral health, pharmacy, and inpatient and outpatient services. These medical costs were partially offset by the rate updates that went into effect in the first and second quarters.
- The Medicare MCR for the second quarter of 2025 was 90.0% and reflects higher utilization among high-acuity members, particularly for long-term services and supports and pharmacy.
- The Marketplace MCR for the second quarter of 2025 was 85.4%. Within that result, approximately 300 basis points was due to prior year member reconciliations and a higher “new store” MCR related to the ConnectiCare acquisition. Excluding these items, the Marketplace MCR was approximately 82.4% and above expectations due to higher utilization relative to risk adjustment.
General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the second quarter of 2025 were 6.2% and 6.1%, respectively, reflecting the benefit of one-time items and continued operating discipline.
Balance Sheet
Cash and investments at the parent company were approximately
Days in claims payable at
Cash Flow
Operating cash flow for the six months ended
2025 Guidance
Premium revenue guidance for the full year is unchanged and expected to be approximately
The Company now expects its full year 2025 GAAP earnings to be no less than
Guidance metrics are summarized below:
|
|
Full Year 2025 Guidance |
|
|
|
|
Premium Revenue |
|
|
|
|
Total Revenue |
|
|
|
|
GAAP Net Income |
|
|
|
|
Adjusted Net Income |
|
|
|
|
GAAP EPS – Diluted |
≥ |
|
|
|
Adjusted EPS – Diluted |
≥ |
|
|
|
Diluted weighted average shares |
54.1M |
|
|
|
|
|
|
|
|
MCR |
90.2% |
|
|
|
Medicaid |
90.9% |
|
|
|
Medicare |
90.0% |
|
|
|
Marketplace |
85.1% |
|
|
|
|
|
|
|
|
GAAP G&A Ratio |
6.7% |
|
|
|
Adjusted G&A Ratio |
6.6% |
|
|
|
Effective Tax Rate |
25.3% |
|
|
|
GAAP Pre-tax Margin |
2.8% |
|
|
|
Adjusted Pre-tax Margin |
3.1% |
|
|
|
|
|
|
|
|
See the Reconciliations of Unaudited Non-GAAP Financial Measures at the end of this release. |
||
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s second quarter results for the period ended
About
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2025 guidance and long-term performance outlook, trends with respect to rates, utilization and medical costs, and our management’s plans and objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
|
|
Three Months Ended |
|
Six Months Ended |
|||||||||
|
|
|
|
|
|||||||||
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|
|
|
|
|
|
|
|
|
|||||
|
|
(In millions, except per-share amounts) |
|||||||||||
|
Revenue: |
|
|
|
|
|
|
|
|||||
|
Premium revenue |
$ |
10,868 |
|
$ |
9,446 |
|
$ |
21,496 |
|
$ |
18,950 |
|
|
Premium tax revenue |
|
431 |
|
|
298 |
|
|
819 |
|
|
595 |
|
|
Investment income |
|
106 |
|
|
115 |
|
|
214 |
|
|
223 |
|
|
Other revenue |
|
22 |
|
|
21 |
|
|
45 |
|
|
43 |
|
|
Total revenue |
|
11,427 |
|
|
9,880 |
|
|
22,574 |
|
|
19,811 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|||||
|
Medical care costs |
|
9,829 |
|
|
8,368 |
|
|
19,308 |
|
|
16,782 |
|
|
General and administrative expenses |
|
711 |
|
|
691 |
|
|
1,485 |
|
|
1,402 |
|
|
Premium tax expenses |
|
431 |
|
|
298 |
|
|
819 |
|
|
595 |
|
|
Depreciation and amortization |
|
58 |
|
|
46 |
|
|
106 |
|
|
91 |
|
|
Other |
|
25 |
|
|
43 |
|
|
50 |
|
|
81 |
|
|
Total operating expenses |
|
11,054 |
|
|
9,446 |
|
|
21,768 |
|
|
18,951 |
|
|
Operating income |
|
373 |
|
|
434 |
|
|
806 |
|
|
860 |
|
|
Interest expense |
|
48 |
|
|
28 |
|
|
91 |
|
|
55 |
|
|
Income before income tax expense |
|
325 |
|
|
406 |
|
|
715 |
|
|
805 |
|
|
Income tax expense |
|
70 |
|
|
105 |
|
|
162 |
|
|
203 |
|
|
Net income |
$ |
255 |
|
$ |
301 |
|
$ |
553 |
|
$ |
602 |
|
|
|
|
|
|
|
|
|
|
|||||
|
Net income per share – Diluted |
$ |
4.75 |
|
$ |
5.17 |
|
$ |
10.19 |
|
$ |
10.33 |
|
|
|
|
|
|
|
|
|
|
|||||
|
Diluted weighted average shares outstanding |
|
53.7 |
|
|
58.2 |
|
|
54.3 |
|
|
58.3 |
|
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
Unaudited |
|
|
||||
|
|
(Dollars in millions, except per-share amounts) |
||||||
|
ASSETS |
|||||||
|
Current assets: |
|
|
|
||||
|
Cash and cash equivalents |
$ |
4,499 |
|
|
$ |
4,662 |
|
|
Investments |
|
4,310 |
|
|
|
4,325 |
|
|
Receivables |
|
3,865 |
|
|
|
3,299 |
|
|
Prepaid expenses and other current assets |
|
438 |
|
|
|
487 |
|
|
Total current assets |
|
13,112 |
|
|
|
12,773 |
|
|
Property, equipment, and capitalized software, net |
|
305 |
|
|
|
288 |
|
|
|
|
2,168 |
|
|
|
1,938 |
|
|
Restricted investments |
|
291 |
|
|
|
286 |
|
|
Deferred income taxes, net |
|
185 |
|
|
|
207 |
|
|
Other assets |
|
148 |
|
|
|
138 |
|
|
Total assets |
$ |
16,209 |
|
|
$ |
15,630 |
|
|
|
|
|
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|||||||
|
Current liabilities: |
|
|
|
||||
|
Medical claims and benefits payable |
$ |
4,885 |
|
|
$ |
4,640 |
|
|
Amounts due government agencies |
|
1,821 |
|
|
|
1,874 |
|
|
Accounts payable, accrued liabilities and other |
|
1,113 |
|
|
|
1,331 |
|
|
Deferred revenue |
|
57 |
|
|
|
51 |
|
|
Total current liabilities |
|
7,876 |
|
|
|
7,896 |
|
|
Long-term debt |
|
3,375 |
|
|
|
2,923 |
|
|
Finance lease liabilities |
|
188 |
|
|
|
195 |
|
|
Other long-term liabilities |
|
167 |
|
|
|
120 |
|
|
Total liabilities |
|
11,606 |
|
|
|
11,134 |
|
|
Stockholders’ equity: |
|
|
|
||||
|
Common stock, |
|
— |
|
|
|
— |
|
|
Preferred stock, |
|
— |
|
|
|
— |
|
|
Additional paid-in capital |
|
454 |
|
|
|
462 |
|
|
Accumulated other comprehensive loss |
|
(10 |
) |
|
|
(57 |
) |
|
Retained earnings |
|
4,159 |
|
|
|
4,091 |
|
|
Total stockholders’ equity |
|
4,603 |
|
|
|
4,496 |
|
|
Total liabilities and stockholders’ equity |
$ |
16,209 |
|
|
$ |
15,630 |
|
|
|
|
|
|
||||
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
Six Months Ended |
||||||
|
|
|
||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
|
|
|
||||
|
|
(In millions) |
||||||
|
Operating activities: |
|
|
|
||||
|
Net income |
$ |
553 |
|
|
$ |
602 |
|
|
Adjustments to reconcile net income to net cash used in operating activities: |
|
|
|
||||
|
Depreciation and amortization |
|
106 |
|
|
|
91 |
|
|
Deferred income taxes |
|
22 |
|
|
|
21 |
|
|
Share-based compensation |
|
30 |
|
|
|
68 |
|
|
Other, net |
|
— |
|
|
|
4 |
|
|
Changes in operating assets and liabilities: |
|
|
|
||||
|
Receivables |
|
(466 |
) |
|
|
(5 |
) |
|
Prepaid expenses and other current assets |
|
10 |
|
|
|
16 |
|
|
Medical claims and benefits payable |
|
(50 |
) |
|
|
(48 |
) |
|
Amounts due government agencies |
|
(81 |
) |
|
|
(43 |
) |
|
Accounts payable, accrued liabilities and other |
|
(301 |
) |
|
|
(307 |
) |
|
Deferred revenue |
|
(59 |
) |
|
|
(405 |
) |
|
Income taxes |
|
124 |
|
|
|
1 |
|
|
Net cash used in operating activities |
|
(112 |
) |
|
|
(5 |
) |
|
Investing activities: |
|
|
|
||||
|
Purchases of investments |
|
(421 |
) |
|
|
(594 |
) |
|
Proceeds from sales and maturities of investments |
|
717 |
|
|
|
506 |
|
|
Net cash paid in business combinations |
|
(245 |
) |
|
|
(295 |
) |
|
Purchases of property, equipment, and capitalized software |
|
(64 |
) |
|
|
(54 |
) |
|
Other, net |
|
18 |
|
|
|
2 |
|
|
Net cash provided by (used in) investing activities |
|
5 |
|
|
|
(435 |
) |
|
Financing activities: |
|
|
|
||||
|
Proceeds from borrowings under credit facility and term loan |
|
650 |
|
|
|
— |
|
|
Common stock purchases |
|
(500 |
) |
|
|
— |
|
|
Repayment of credit facility and term loan |
|
(200 |
) |
|
|
— |
|
|
Common stock withheld to settle employee tax obligations |
|
(36 |
) |
|
|
(56 |
) |
|
Other, net |
|
44 |
|
|
|
6 |
|
|
Net cash used in financing activities |
|
(42 |
) |
|
|
(50 |
) |
|
Net decrease in cash, cash equivalents, and restricted cash and cash
|
|
(149 |
) |
|
|
(490 |
) |
|
Cash, cash equivalents, and restricted cash and cash equivalents at
|
|
4,741 |
|
|
|
4,908 |
|
|
Cash, cash equivalents, and restricted cash and cash equivalents at end of
|
$ |
4,592 |
|
|
$ |
4,418 |
|
|
|
|
|
|
||||
UNAUDITED SEGMENT DATA
(Dollars in millions)
|
|
|
|
|
|
|
|
|
|
|
2025 |
|
2024 |
|
2024 |
|
Ending Membership by Segment: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medicaid |
4,774,000 |
|
4,890,000 |
|
4,942,000 |
|
|
Medicare |
267,000 |
|
242,000 |
|
251,000 |
|
|
Marketplace |
690,000 |
|
403,000 |
|
386,000 |
|
|
Other |
|
15,000 |
|
— |
|
— |
|
Total |
5,746,000 |
|
5,535,000 |
|
5,579,000 |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
||||||||||||||||
|
|
2025 |
|
2024 |
||||||||||||||
|
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
||||||
|
|
|
|
|
|
|
||||||||||||
|
Medicaid |
$ |
8,029 |
|
$ |
697 |
|
91.3 |
% |
|
$ |
7,378 |
|
$ |
683 |
|
90.8 |
% |
|
Medicare |
|
1,608 |
|
|
161 |
|
90.0 |
|
|
|
1,441 |
|
|
217 |
|
84.9 |
|
|
Marketplace |
|
1,200 |
|
|
175 |
|
85.4 |
|
|
|
627 |
|
|
178 |
|
71.6 |
|
|
Other |
|
31 |
|
|
6 |
|
82.7 |
|
|
|
— |
|
|
— |
|
— |
|
|
Consolidated |
$ |
10,868 |
|
$ |
1,039 |
|
90.4 |
% |
|
$ |
9,446 |
|
$ |
1,078 |
|
88.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
Six Months Ended |
||||||||||||||||
|
|
2025 |
|
2024 |
||||||||||||||
|
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
|
Premium Revenue |
|
Medical Margin |
|
MCR (1) |
||||||
|
|
|
|
|
|
|
||||||||||||
|
Medicaid |
$ |
16,159 |
|
$ |
1,488 |
|
90.8 |
% |
|
$ |
14,870 |
|
$ |
1,458 |
|
90.2 |
% |
|
Medicare |
|
3,076 |
|
|
333 |
|
89.2 |
|
|
|
2,883 |
|
|
380 |
|
86.8 |
|
|
Marketplace |
|
2,204 |
|
|
358 |
|
83.7 |
|
|
|
1,197 |
|
|
330 |
|
72.4 |
|
|
Other |
|
57 |
|
|
9 |
|
85.0 |
|
|
|
— |
|
|
— |
|
— |
|
|
Consolidated |
$ |
21,496 |
|
$ |
2,188 |
|
89.8 |
% |
|
$ |
18,950 |
|
$ |
2,168 |
|
88.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
(1) The MCR represents medical costs as a percentage of premium revenue. |
|||||||||||||||||
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
|
Six Months Ended |
|||||||
|
|
|
||||||
|
|
|
2025 |
|
|
|
2024 |
|
|
|
|
|
|
||||
|
|
Unaudited |
||||||
|
Medical claims and benefits payable, beginning balance |
$ |
4,640 |
|
|
$ |
4,204 |
|
|
Components of medical care costs related to: |
|
|
|
||||
|
Current year |
|
19,509 |
|
|
|
17,301 |
|
|
Prior year |
|
(201 |
) |
|
|
(519 |
) |
|
Total medical care costs |
|
19,308 |
|
|
|
16,782 |
|
|
Payments for medical care costs related to: |
|
|
|
||||
|
Current year |
|
15,700 |
|
|
|
13,429 |
|
|
Prior year |
|
3,918 |
|
|
|
3,161 |
|
|
Total paid |
|
19,618 |
|
|
|
16,590 |
|
|
Acquired balances, net of post-acquisition adjustments |
|
295 |
|
|
|
421 |
|
|
Change in non-risk and other payables |
|
260 |
|
|
|
(240 |
) |
|
Medical claims and benefits payable, ending balance |
$ |
4,885 |
|
|
$ |
4,577 |
|
|
|
|
|
|
||||
|
Days in Claims Payable (1) |
|
43 |
|
|
|
50 |
|
|
|
|
|
|
||||
__________________
|
(1) |
The Company calculates Days in Claims Payable using claims incurred but not paid, or IBNP, and other fee-for-service payables included in medical claims and benefits payable, and quarterly fee-for-service related costs included in medical care costs within the Company’s consolidated financial statements. |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted after-tax margin represents adjusted net income, divided by total revenue.
|
|
Three Months Ended |
|
Six Months Ended |
||||||||||||||||||||||||||||
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
|||||||||||||||||||||
|
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
|
Amount |
|
Per Diluted Share |
||||||||||||||||
|
GAAP Net income |
$ |
255 |
|
|
$ |
4.75 |
|
|
$ |
301 |
|
|
$ |
5.17 |
|
|
$ |
553 |
|
|
$ |
10.19 |
|
|
$ |
602 |
|
|
$ |
10.33 |
|
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
|
Amortization of
|
$ |
32 |
|
|
$ |
0.60 |
|
|
$ |
21 |
|
|
$ |
0.36 |
|
|
$ |
53 |
|
|
$ |
0.99 |
|
|
$ |
41 |
|
|
$ |
0.71 |
|
|
Acquisition-related
|
|
19 |
|
|
|
0.37 |
|
|
|
18 |
|
|
|
0.31 |
|
|
|
42 |
|
|
|
0.78 |
|
|
|
35 |
|
|
|
0.60 |
|
|
Other (2) |
|
— |
|
|
|
— |
|
|
|
14 |
|
|
|
0.24 |
|
|
|
2 |
|
|
|
0.03 |
|
|
|
20 |
|
|
|
0.35 |
|
|
Subtotal, adjustments |
|
51 |
|
|
|
0.97 |
|
|
|
53 |
|
|
|
0.91 |
|
|
|
97 |
|
|
|
1.80 |
|
|
|
96 |
|
|
|
1.66 |
|
|
Income tax effect |
|
(12 |
) |
|
|
(0.24 |
) |
|
|
(13 |
) |
|
|
(0.22 |
) |
|
|
(23 |
) |
|
|
(0.43 |
) |
|
|
(23 |
) |
|
|
(0.40 |
) |
|
Adjustments, net of tax |
|
39 |
|
|
|
0.73 |
|
|
|
40 |
|
|
|
0.69 |
|
|
|
74 |
|
|
|
1.37 |
|
|
|
73 |
|
|
|
1.26 |
|
|
Adjusted net income |
$ |
294 |
|
|
$ |
5.48 |
|
|
$ |
341 |
|
|
$ |
5.86 |
|
|
$ |
627 |
|
|
$ |
11.56 |
|
|
$ |
675 |
|
|
$ |
11.59 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
__________________
|
(1) |
Reflects non-recurring costs associated with acquisitions, including various transaction and certain integration costs. |
||
|
(2) |
The six months ended |
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
2025 GUIDANCE
|
|
Amount |
|
Per Diluted Share (2) |
||||
|
GAAP Net income |
$ |
912 |
|
|
$ |
16.90 |
|
|
Adjustments: |
|
|
|
||||
|
Amortization of intangible assets |
|
90 |
|
|
|
1.67 |
|
|
Acquisition-related expenses |
|
60 |
|
|
|
1.10 |
|
|
Other |
|
2 |
|
|
|
0.03 |
|
|
Subtotal, adjustments |
|
152 |
|
|
|
2.80 |
|
|
Income tax effect (1) |
|
(36 |
) |
|
|
(0.70 |
) |
|
Adjustments, net of tax |
|
116 |
|
|
|
2.10 |
|
|
Adjusted net income |
$ |
1,028 |
|
|
$ |
19.00 |
|
|
|
|
|
|
||||
__________________
|
(1) |
Income tax effect calculated at the statutory tax rate of approximately 23.9%. |
||
|
(2) |
Computations assume approximately 54.1 million diluted weighted average shares outstanding. |
Non-GAAP Financial Measures
The Company includes in this release the financial measure, “new store embedded earnings,” which is a non-GAAP measure. The term is defined as the incremental diluted earnings per share impact that we expect to achieve between 2026 and 2028 related to newly awarded but not yet commenced state Medicaid contracts, and recently closed and announced acquisitions. The incremental impact reflects the expected full-year earnings for the newly-awarded
View source version on businesswire.com: https://www.businesswire.com/news/home/20250723560684/en/
Investor Contact:
Media Contact:
Source: